Medicine and Dentistry
Glycoprotein IIb/IIIa Inhibitors
100%
Inpatient
72%
Patient
54%
Odds Ratio
36%
Clopidogrel
36%
Bleeding
18%
Arm
18%
Combination Therapy
9%
Myocardial Infarction
9%
Ischemia
9%
Complication
9%
Platelet
9%
Chemotherapeutic Agent
9%
All Cause Mortality
9%
Drug
9%
Revascularization
9%
Stent Thrombosis
9%
Life
9%
Analysis
9%
Therapeutic Procedure
9%
Nursing and Health Professions
Cangrelor
81%
Confidence Interval
36%
Odds Ratio
36%
Percutaneous Coronary Intervention
36%
Clopidogrel
36%
Bleeding
18%
Randomization
18%
Emergency Medical Technician
18%
Complication
9%
Heart Infarction
9%
Combination Therapy
9%
Ischemia
9%
All Cause Mortality
9%
Revascularization
9%
Stent Thrombosis
9%
Standard
9%
Procedures
9%
Analysis
9%
Drug
9%
Eptifibatide
9%
Biochemistry, Genetics and Molecular Biology
Glycoprotein IIb/IIIa
100%
Cangrelor
81%
Clopidogrel
36%
Platelet
9%
All Cause Mortality
9%
P2Y12
9%
Life
9%
Eptifibatide
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clopidogrel
36%
Bleeding
18%
Antagonist
18%
Ischemia
9%
Complication
9%
Drug
9%
Stent Thrombosis
9%
Heart Infarction
9%
All Cause Mortality
9%